ʻO ka hāʻule ʻana o ka naʻau me ka haʻihaʻi ejection hoʻemi ʻia (HFrEF) he ʻano nui o ka puʻuwai puʻuwai, a ua hōʻike ka China HF Study he 42% o ka pau ʻana o ka naʻau ma Kina he HFrEF, ʻoiai ua loaʻa kekahi mau papa lapaʻau maʻamau no HFrEF a ua hōʻemi i ka pilikia. o ka make a me ka halema'i no ka pau ole o ka na'au i kekahi wahi. Eia nō naʻe, ʻoi aku ka nui o ka poʻe maʻi i ka hōʻeha ʻana o ka naʻau i nā hanana, ʻoi aku ka nui o ka make ma kahi o 25% a ʻilihune ka prognosis. No laila, aia nō kahi koi wikiwiki no nā mea lapaʻau hou i ka mālama ʻana i ka HFrEF, a ua aʻo ʻia ʻo Vericiguat, kahi mea hoʻoulu stimulator guanylate cyclase (sGC), i ka noiʻi VICTORIA e loiloi inā hiki iā Vericiguat ke hoʻomaikaʻi i ka wānana o nā maʻi me HFrEF. ʻO ka haʻawina he multicenter, randomized, parallel-group, placebo-controlled, double-blind, event-driven, phase III clinical results study. Hana ʻia ma lalo o ka mana o ka VIGOR Center ma Kanada me ka hui pū me ka Duke Clinical Research Institute, 616 mau kikowaena ma 42 mau ʻāina a me nā ʻāina, me ʻEulopa, Iapana, Kina a me ʻAmelika Hui Pū ʻIa, i komo i ka noiʻi. Hoʻohanohano ʻia kā mākou ʻoihana cardiology e komo. ʻO ka huina o 5,050 mau maʻi me ka maʻi puʻuwai maʻi mau makahiki ≥18 makahiki, NYHA papa II-IV, EF <45%, me ka kiʻekiʻe o ka natriuretic peptide (NT-proBNP) kiʻekiʻe i loko o 30 mau lā ma mua o ka randomization, a ua hoʻopaʻa ʻia i ka hale maʻi no ka pau ʻole o ka naʻau. i loko o 6 mau mahina ma mua o ka randomization a i ʻole nā ​​​​diuretics i lawelawe ʻia i loko o ka puʻuwai i loko o 3 mau mahina ma mua o ka randomization i kākau ʻia i loko o ke aʻo ʻana. ka loaʻa ʻana o ka ESC, AHA/ACC, a me nā alakaʻi kikoʻī o ka ʻāina/ ʻāina i ʻōlelo ʻia no ka mālama ʻana. Ua hoʻokaʻawale ʻia nā maʻi ma kahi ratio 1: 1 i ʻelua mau pūʻulu a hāʻawi ʻiaVericiguat(n=2526) a me kahi placebo (n=2524) ma luna o ka lāʻau lapaʻau maʻamau.
ʻO ka hopena mua o ke aʻo ʻana ʻo ia ka hopena composite o ka make cardiovascular a i ʻole ka hoʻokipa mua ʻana o ka naʻau; ʻO nā helu hope lua i komo i nā ʻāpana o ka hopena mua, nā hale maʻi hōʻino ʻole o ka naʻau mua a ma hope (nā hanana mua a me nā hanana hou), ka hopena hoʻohui o nā kumu āpau a i ʻole ka hoʻomaha ʻana i ka naʻau, a me nā kumu make. Ma kahi median follow-up o 10.8 mahina, aia he 10% ka emi ʻana o ka hopena mua o ka make cardiovascular a i ʻole ka hoʻokipa mua ʻana o ka naʻau ma ka hui Vericiguat i hoʻohālikelike ʻia me ka hui placebo.